Bauml JM - Search Results

1

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.

Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ. Bagley SJ, et al. Among authors: bauml jm. Lung Cancer. 2017 Apr;106:1-7. doi: 10.1016/j.lungcan.2017.01.013. Epub 2017 Jan 25. Lung Cancer. 2017. PMID: 28285682

2

Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?

Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, Evans T, Langer C. Bauml J, et al. Lung Cancer. 2013 Sep;81(3):347-353. doi: 10.1016/j.lungcan.2013.05.011. Epub 2013 Jun 24. Lung Cancer. 2013. PMID: 23806795 Free PMC article.

3

Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies.

Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, Evans T, Langer C. Bauml J, et al. Clin Lung Cancer. 2013 Sep;14(5):581-91. doi: 10.1016/j.cllc.2013.05.002. Epub 2013 Jul 1. Clin Lung Cancer. 2013. PMID: 23827517 Free PMC article.

4

Does perceived control predict Complementary and Alternative Medicine (CAM) use among patients with lung cancer? A cross-sectional survey.

Bauml J, Langer CJ, Evans T, Garland SN, Desai K, Mao JJ. Bauml J, et al. Support Care Cancer. 2014 Sep;22(9):2465-72. doi: 10.1007/s00520-014-2220-5. Epub 2014 Apr 9. Support Care Cancer. 2014. PMID: 24715092 Free PMC article.

5

Do attitudes and beliefs regarding complementary and alternative medicine impact its use among patients with cancer? A cross-sectional survey.

Bauml JM, Chokshi S, Schapira MM, Im EO, Li SQ, Langer CJ, Ibrahim SA, Mao JJ. Bauml JM, et al. Cancer. 2015 Jul 15;121(14):2431-8. doi: 10.1002/cncr.29173. Epub 2015 May 26. Cancer. 2015. PMID: 26011157 Free PMC article.

6

Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.

Brady AK, McNeill JD, Judy B, Bauml J, Evans TL, Cohen RB, Langer C, Vachani A, Aggarwal C. Brady AK, et al. Oncotarget. 2015 Oct 6;6(30):30287-94. doi: 10.18632/oncotarget.4711. Oncotarget. 2015. PMID: 26471290 Free PMC article.

7

PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.

Bagley SJ, Bauml JM, Langer CJ. Bagley SJ, et al. Among authors: bauml jm. Clin Adv Hematol Oncol. 2015 Oct;13(10):676-83. Clin Adv Hematol Oncol. 2015. PMID: 27058572 Review.

8

Acupuncture for Dyspnea in Lung Cancer: Results of a Feasibility Trial.

Bauml J, Haas A, Simone CB 2nd, Li SQ, Cohen RB, Langer CJ, Mao JJ. Bauml J, et al. Integr Cancer Ther. 2016 Sep;15(3):326-32. doi: 10.1177/1534735415624138. Epub 2016 Apr 24. Integr Cancer Ther. 2016. PMID: 27114385 Free PMC article.

9

Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma.

Weiss JM, Bagley S, Hwang WT, Bauml J, Olson JG, Cohen RB, Hayes DN, Langer C. Weiss JM, et al. Among authors: bauml j. Cancer. 2016 Aug 1;122(15):2350-5. doi: 10.1002/cncr.30067. Epub 2016 May 19. Cancer. 2016. PMID: 27197056 Free article.

10

Immunotherapy for head and neck cancer: latest developments and clinical potential.

Bauml JM, Cohen RB, Aggarwal C. Bauml JM, et al. Ther Adv Med Oncol. 2016 May;8(3):168-75. doi: 10.1177/1758834016631529. Epub 2016 Feb 16. Ther Adv Med Oncol. 2016. PMID: 27239235 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters